Wegovy (Semaglutide): The Clinical Trial Evidence Behind the Weight Loss Approval | Research

The takeaway

Three major clinical trial programs showed semaglutide produces superior weight loss compared to placebo and other diabetes drugs, leading to FDA approval of Wegovy for chronic weight management.

Superior to placebo and other drugs across 3 trial programs
Semaglutide demonstrated consistent weight loss superiority in SUSTAIN (diabetes, injectable), PIONEER (diabetes, oral), and STEP (obesity, injectable) — the evidence base for Wegovy's FDA approval

What the researchers found

This review summarizes weight loss results from three major semaglutide clinical trial programs: SUSTAIN (1.0 mg weekly injection for type 2 diabetes), PIONEER (oral semaglutide for type 2 diabetes), and STEP (2.4 mg weekly injection for obesity without diabetes). All three programs demonstrated that semaglutide — both injected and oral — produced superior weight loss compared to placebo and other antidiabetic medications. These results collectively supported the FDA approval of Wegovy (semaglutide 2.4 mg) as a dedicated weight loss medication.

Why it matters

This review documents the clinical evidence that transformed semaglutide from a diabetes drug into the first blockbuster GLP-1 weight loss medication. The STEP program in particular showed that a higher dose of semaglutide could produce substantial weight loss in people with obesity regardless of diabetes status, opening a massive new market for peptide-based therapeutics.

The numbers in context

Semaglutide doses: 1.0 mg (diabetes) and 2.4 mg (obesity) weekly SC; oral formulation also studied · 3 trial programs: SUSTAIN, PIONEER, STEP · FDA-approved as Wegovy for chronic weight management

How the study worked

Literature review summarizing data from the SUSTAIN, PIONEER, and STEP clinical trial programs. Trial data obtained from ClinicalTrials.gov and PubMed databases.

Who was studied

Adults with type 2 diabetes (SUSTAIN, PIONEER) and adults with obesity or overweight with comorbidities (STEP)

What this study cannot tell us

This is a narrative literature review, not a systematic review or meta-analysis. Published shortly after Wegovy's approval, it captures early trial data but not longer-term real-world outcomes or the cardiovascular benefit data (SELECT trial) that came later. Does not discuss tirzepatide or other emerging competitors.

How to read the evidence

This review synthesizes data from three large, well-designed clinical trial programs (SUSTAIN, PIONEER, STEP) that included multiple randomized, double-blind, placebo-controlled trials with thousands of participants. The underlying evidence is strong, though the review itself is narrative rather than systematic.

When this study was published

Published in early 2022, shortly after Wegovy's FDA approval in June 2021. It does not include the SELECT cardiovascular outcome trial data (2023) or real-world effectiveness data that have since accumulated. The landscape has also expanded with tirzepatide and other competitors.

The bigger picture

Wegovy's approval in 2021 marked a turning point in obesity treatment — the first time a GLP-1 peptide drug was approved specifically for weight management rather than diabetes. It validated the concept that gut hormone peptides could be powerful anti-obesity tools and paved the way for the explosion of GLP-1 RA demand, tirzepatide, and the broader 'weight loss drug revolution' that followed.

Questions still open

How does semaglutide's weight loss efficacy compare to newer dual and triple agonists like tirzepatide and retatrutide?
What happens to weight when patients stop semaglutide — is long-term or lifelong treatment necessary?
Can the oral formulation of semaglutide achieve comparable weight loss to the injectable version at optimized doses?

Common questions

What's the difference between Ozempic and Wegovy if they're both semaglutide?

Ozempic (semaglutide 0.5-1.0 mg weekly) is FDA-approved for type 2 diabetes, while Wegovy (semaglutide 2.4 mg weekly) is approved specifically for chronic weight management. They contain the same active ingredient but at different doses and with different approved uses, which affects insurance coverage and prescribing.

How much weight can you lose on Wegovy based on the clinical trials?

In the STEP trials, participants taking semaglutide 2.4 mg lost significantly more weight than those on placebo. The specific percentages varied by trial, but semaglutide consistently outperformed both placebo and comparator medications. Individual results depend on factors like starting weight, diet, and exercise.

Read the original research

Wegovy (semaglutide): a new weight loss drug for chronic weight management.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 70(1), 5-13

View on PubMed ↗Publisher’s paper ↗

Citation

Singh, Gurdeep; Krauthamer, Matthew; Bjalme-Evans, Meghan. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management.. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 70(1), 5-13. https://doi.org/10.1136/jim-2021-001952